Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
Nathan P Wiederhold Departments of Pathology and Medicine/Infectious Diseases, University of Texas Health Science Center at San Antonio, South Texas Reference Laboratories, San Antonio, TX, USA Abstract: Posaconazole is a broad-spectrum triazole antifungal agent with potent activity against various...
Main Author: | Wiederhold NP |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-12-01
|
Series: | Clinical Pharmacology : Advances and Applications |
Subjects: | |
Online Access: | https://www.dovepress.com/pharmacokinetics-and-safety-of-posaconazole-delayed-release-tablets-fo-peer-reviewed-article-CPAA |
Similar Items
-
Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient
by: Diego O. Andrey, et al.
Published: (2017-02-01) -
Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
by: Leelawattanachai P, et al.
Published: (2019-04-01) -
Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients
by: Fekade B. Sime, et al.
Published: (2019-06-01) -
Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats
by: Yang S, et al.
Published: (2021-05-01) -
The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies
by: Veselov A.V.
Published: (2020-05-01)